NCT01602406View on ClinicalTrials.gov

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 21, 2012

Primary Completion Date

August 2, 2017

Study Completion Date

August 2, 2017

Conditions
Advanced HER2-positive Breast Cancer or Gastric Cancer
Interventions
DRUG

LJM716

LJM716

DRUG

Trastuzumab

Trastuzumab

Trial Locations (11)

2610

Novartis Investigative Site, Wilrijk

10002

Novartis Investigative Site, Taipei

19111

Novartis Investigative Site, Philadelphia

20133

Novartis Investigative Site, Milan

27514

Novartis Investigative Site, Chapel Hill

44805

Novartis Investigative Site, Saint-Herblain

46010

Novartis Investigative Site, Valencia

02114

Novartis Investigative Site, Boston

1066 CX

Novartis Investigative Site, Amsterdam

03080

Novartis Investigative Site, Seoul

OX3 7LJ

Novartis Investigative Site, Oxford

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY